MTTI Reports on 225Ac-EBTATE and 177Lu-EBTATE at 2024 SNMMI Annual Meeting

Molecular Targeting Technologies, Inc. (MTTI) is preparing to unveil significant updates on its 177Lu-EBTATE clinical trials and 225Ac-EBTATE preclinical research at the upcoming 2024 SNMMI meeting in Toronto, scheduled for June 8-11. These findings will be showcased at booth #1819 during the exhibition.

177Lu-EBTATE® is a pioneering EvaThera drug, known as the first patented long-acting peptide targeted radiotherapeutic. This drug specifically binds to somatostatin receptor 2 found on neuroendocrine tumors and other similar malignancies, subsequently destroying them with its radionuclide payload. A distinct feature of EBTATE is its incorporation of Evans blue, which binds to serum albumin, thereby prolonging the drug’s circulatory half-life and tumor residence. This enhancement allows for effective treatment with lower radiopharmaceutical dosages and fewer cycles compared to the current standard of care (SOC). The advantageous properties of 177Lu-EBTATE have also been observed in studies involving its 225Ac-EBTATE counterpart.

Professor Zhaohui Zhu from Peking Union Medical College Hospital shared insights from a three-year follow-up study involving 30 patients with metastatic neuroendocrine tumors (mNETs). The results indicated that 177Lu-EBTATE is safe, showing no nephrotoxicity or hepatotoxicity, and exhibited an 86% disease control rate while using 60% less radioactivity than 177Lu-DOTATATE. Additionally, the incidence of grade 3 hematoxicity was low (3.4% compared to 15% reported in SOC), with no long-term nephrotoxicity recorded.

The study on the efficacy of long-acting 225Ac-EBTATE against somatostatin receptor-2-positive small-cell lung cancer (SCLC) has been accepted for presentation at the 2024 SNMMI. Professor Humphrey Fonge from the University of Saskatchewan noted that 225Ac-EBTATE, when administered twice at 30 kBq doses 10 days apart, was highly effective in treating SCLC. The treatment resulted in 80% complete remission and 100% survival rates. Compared to 225Ac-DOTATATE, 225Ac-EBTATE achieved twice the tumor growth inhibition with 60% less radioactivity. Moreover, toxicity assessments based on body weight, blood counts, and chemistry demonstrated that 225Ac-EBTATE was well-tolerated and highly effective.

Chris Pak, President and CEO of MTTI, expressed satisfaction with the findings, highlighting that 177Lu-EBTATE showed no safety issues and was effective at a lower dose than SOC in mNET patients. He also emphasized the promising preclinical results of 225Ac-EBTATE, which provided significantly greater tumor growth inhibition at a lower radioactivity dose compared to 225Ac-DOTATATE. Pak indicated that MTTI is eager to advance clinical trials involving these radiotherapeutic drugs for small-cell lung cancer and other cancers.

Molecular Targeting Technologies, Inc. (MTTI) is a private, clinical-stage biotechnology company focused on developing targeted radiotherapeutics for rare cancers. The company's mission is to translate innovative radiopharmaceuticals into improved health outcomes.